|drug3123||Prospective study with two measurement points investigating the impact of viral mitigation protocols on mental health Wiki||0.58|
|D011024||Pneumonia, Viral NIH||0.11|
|D045169||Severe Acute Respiratory Syndrome NIH||0.04|
There is one clinical trial.
coronavirus disease 2019 related pneumonia is causing acute respiratory failure and this is the most common reason for ICU admission. We have several different way for respiratory support. HFNC is one of the new technics for oxygen support. Our main purpose to observe the effect of HFNC on coronavirus disease 2019 patients' ICU stay and mortality.
Description: the mortality rate of patientsMeasure: short term mortality Time: in 28 days.
Description: means the stay day of patients in intensive care unitMeasure: icu stay Time: up to 28 days
Description: partial oxygen pressure, partial carbon dioxide pressure . both measured in mmhgMeasure: blood gases Time: at the admission time and 24th hour
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports